[1]. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Cancer immunology, immunotherapy : CII （2023年） [査読] 有
[DOI] [2]. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
NPJ precision oncology [巻]6 [号]1 [頁]88 （2022年） [査読] 有
[DOI] [3]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Journal of cancer research and clinical oncology （2022年） [査読] 有
[DOI] [4]. Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.
eLife [巻]10 （2021年） [査読] 有
[DOI] [5]. Longitudinal Assessment of Real-World Treatments and Outcomes in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Prospective, Observational Study
European Journal of Respiratory Medicine （2024年） [査読] 有
[6]. Characterization of BRAFT599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling.
JCO precision oncology [巻]8 [頁]e2300538 （2024年） [査読] 有
[DOI] [機関リポジトリ][7]. Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.
Respiratory research [巻]25 [号]1 [頁]25 -25 （2024年） [査読] 有
[DOI] [8]. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study.
Emerging microbes & infections [巻]12 [号]1 [頁]2155250 （2023年） [査読] 有
[DOI] [9]. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy
Cancer Immunol Immunother [巻]72 [頁]2717 -2728 （2023年） [査読] 有
[10]. Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study.
Journal for immunotherapy of cancer [巻]11 [号]7 （2023年） [査読] 有
[DOI] [11]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer
J Cancer Res Clin Oncol [巻]149 [頁]2963 -2974 （2023年） [査読] 有
[12]. A predictive model for acute exacerbation of idiopathic interstitial pneumonias.
The European respiratory journal （2023年） [査読] 有
[DOI] [機関リポジトリ][13]. CD109 on Dendritic Cells Regulates Airway Hyperreactivity and Eosinophilic Airway Inflammation.
American journal of respiratory cell and molecular biology [巻]68 [号]2 [頁]201 -212 （2023年） [査読] 有
[DOI] [14]. Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer.
Global health & medicine [巻]4 [号]6 [頁]301 -308 （2022年） [査読] 有
[DOI] [15]. Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume.
The European respiratory journal [巻]60 [号]6 （2022年） [査読] 有
[DOI] [16]. Prognostic significance of radiological pleuroparenchymal fibroelastosis in complex lung disease: a multicentre retrospective cohort study.
Thorax （2022年） [査読] 有
[DOI] [17]. Clinical practice of high-flow nasal cannula therapy in COVID-19 pandemic era: a cross-sectional survey of respiratory physicians.
Respiratory investigation [巻]60 [号]6 [頁]779 -786 （2022年） [査読] 有
[DOI] [18]. Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.
Targeted oncology [巻]17 [号]5 [頁]583 -589 （2022年） [査読] 有
[DOI] [機関リポジトリ][19]. Effect of Hypoxia on Pulmonary Endothelial Cells from Bleomycin-Induced Pulmonary Fibrosis Model Mice.
International journal of molecular sciences [巻]23 [号]16 （2022年） [査読] 有
[DOI] [20]. Associations of serum long-chain fatty acids with multiple organ involvement in patients with sarcoidosis.
BMC pulmonary medicine [巻]22 [号]1 [頁]290 （2022年） [査読] 有
[DOI] [21]. Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis.
Respiratory research [巻]23 [号]1 [頁]142 （2022年） [査読] 有
[DOI] [22]. Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.
BMC pulmonary medicine [巻]22 [号]1 [頁]186 （2022年） [査読] 有
[DOI] [23]. EGFR-mutated, metastatic pulmonary pleomorphic carcinoma successfully treated with afatinib
Current Problems in Cancer: Case Reports （2022年） [査読] 有
[24]. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
Thorax （2022年） [査読] 有
[DOI] [機関リポジトリ][25]. mA demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer.
Cancer gene therapy （2022年） [査読] 有
[DOI] [26]. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.
Respiratory research [巻]23 [号]1 [頁]57 （2022年） [査読] 有
[DOI] [27]. Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-Small Cell Lung Cancer After Nivolumab Therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) [巻]45 [号]2 [頁]125 -131 （2022年） [査読] 有
[DOI] [28]. Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the mutation.
Respiratory medicine case reports [巻]36 [頁]101608 （2022年） [査読] 有
[DOI] [29]. Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report.
Respiratory medicine case reports [巻]37 [頁]101632 （2022年） [査読] 有
[DOI] [30]. Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Cancer immunology, immunotherapy : CII [巻]71 [号]1 [頁]203 -217 （2022年） [査読] 有
[DOI] [31]. EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
JTO clinical and research reports [巻]3 [号]1 [頁]100264 （2022年） [査読] 有
[DOI] [32]. Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.
JTO clinical and research reports [巻]3 [号]1 [頁]100263 （2022年） [査読] 有
[DOI] [33]. Transient leukocytopenia following combination therapy for COVID-19.
Respiratory investigation [巻]60 [号]1 [頁]158 -161 （2022年） [査読] 有
[DOI] [34]. Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
BMC pulmonary medicine [巻]21 [号]1 [頁]409 （2021年） [査読] 有
[DOI] [35]. MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
JTO clinical and research reports [巻]2 [号]11 [頁]100239 （2021年） [査読] 有
[DOI] [36]. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
BMC pulmonary medicine [巻]21 [号]1 [頁]309 （2021年） [査読] 有
[DOI] [37]. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
Scientific reports [巻]11 [号]1 [頁]14999 （2021年） [査読] 有
[DOI] [38]. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Oncoimmunology [巻]10 [号]1 [頁]1962656 （2021年） [査読] 有
[DOI] [39]. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Cancer treatment and research communications [巻]29 [頁]100493 （2021年） [査読] 有
[DOI] [40]. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
JAMA network open [巻]3 [号]9 [頁]e2011818 （2020年） [査読] 有
[DOI] [41]. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) [巻]141 [頁]21 -31 （2020年） [査読] 有
[DOI] [42]. CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer.
Oncoimmunology [巻]9 [号]1 [頁]1746554 （2020年） [査読] 有
[DOI] [43]. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Lung cancer (Amsterdam, Netherlands) [巻]134 [頁]202 -209 （2019年） [査読] 有
[DOI] [44]. Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [巻]14 [号]4 [頁]656 -671 （2019年） [査読] 有
[DOI]